Agenus Therapeutics Reports GlaxoSmithKline's Magrit Study Does Not Meet First or Second Primary Endpoint
March 20, 2014 at 06:12 AM EDT
Agenus (NASDAQ: AGEN) today announced that GlaxoSmithKline's (NYSE: GSK) MAGRITi study, a Phase 3 randomized, blinded, ...